Scholar Rock (SRRK)
(Delayed Data from NSDQ)
$7.42 USD
+0.35 (4.95%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $7.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SRRK 7.42 +0.35(4.95%)
Will SRRK be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for SRRK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRRK
Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High?
Here's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation (SRRK)
SRRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong Buy
Wall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 203.99%: Read This Before Placing a Bet
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
Other News for SRRK
Scholar Rock price target raised by $2 at Wedbush, here's why
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock: Enrollment complete in Phase 2 trial of apitegromab for obesity
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer